Dr Talia Biran | Medical Affairs Lead, Oncology
Lexicon Pharma

Talia Biran has been Executive Director, Medical Affairs, Oncology at Lexicon since 2013.

Talia  is a Global Medical Affairs leader who brings more than 20 years of divers experience in pharmaceutical industry, having worked in companies such as, Novartis, Merck and Janssen, with particular expertise in Oncology, infectious disease and endocrinology. Talia brings in-depth understanding of drug development across all stages of development, therapeutic area, scientific and market needs. Over the years, Talia has successfully contributed to the development approval and launch of several drugs, including Abiraterone Acetate (Zytiga ®, prostate cancer), Vorinostat ( Zolinza®, CTCL) ,  Letrozole (Femara®, breast cancer), and Octreotide ( Sandostatin LAR® , neuroendocrine tumors (NETs) and acromegaly).

Prior to Joining Lexicon, Talia worked at Janssen R&D, Inc. where she directed clinical operation efforts for global Phase I-III R&D and Medical Affair programs of Abiraterone Acetate (ZYTIGA) in Metastatic Prostate Cancer resulting in successful worldwide NDA submission and FDA approval.

Prior to Janssen, Talia was a Medical Science Liaison for Merck Oncology where she  served as the primary conduit for scientific and medical exchange with national investigators and key opinion leaders at academic institutions and  cooperative groups and  provided guidance and expertise to the design of phase I-IV  clinical trials and LCM development. She led the development of a strategic global collaborative partnership between Merck Research Labs and 16 major global cancer centers with early development capabilities (MRL Oncology Network- OncoNet) to advance scientific collaborations of shared interest which enhanced the execution of Phase II-III clinical trials for Merck’s oncology compounds in development across multiple tumor types.

Prior to Merck , Talia  worked at Novartis Oncology GMA , where she interfaced with Marketing, trained global Medical Liaisons  and  directed the  development and implementation of   scientific communication ,publication strategies, and programs supporting pipeline and marketed products worth over  $2 billion in sales,

Talia holds a Master’s of Science (M.Sc) in Microbiology from Tel-Aviv University, Department of Life Sciences, and Tel-Aviv, Israel. Her Thesis, under the supervision of Professor Sara Lavi, focused on Gene Amplification of  SV-40 and it’s link to tumorogenesis.